q&more
My watch list
my.chemie.de  
Login  

News

Alzheimer’s disease: Protective immune response in the brain?

TheDigitalArtist, pixabay.com, CC0

Symbolic image

02-Sep-2019: LMU researchers Christian Haass and Michael Ewers have identified a factor that might possibly delay the emergence and slow the progression of Alzheimer’s disease.

Researchers at the German Center for Neurodegenerative Diseases (DZNE) and the Institute for Stroke and Dementia Research (ISD) at the LMU Medical Center have found that a protein named TREM2 may have a mitigating effect on the course of Alzheimer’s disease. In a new study led by Professor Christian Haass (LMU, DZNE) and Professor Michael Ewers (ISD, LMU), patients who have higher levels of TREM2 in their cerebrospinal fluid (CSF) at various stages of the disease have a better prognosis than those in whom the protein is present in lower amounts. This observation provides a starting point for the development of new therapeutic strategies.

In the brain, TREM2 is produced exclusively by the microglia, which serve as the organ’s immune cells. These cells patrol the brain, disposing of cellular waste products and abnormal extracellular deposits. Earlier studies carried out by Haass and his colleagues in mice had shown that TREM2 activates microglia to enclose and selectively destroy toxic protein aggregates typical for Alzheimer’s disease. These observations suggested that TREM2 might protect the brain from the degenerative effects of Alzheimer’s – at least in the mouse model. But can these results be extended to Alzheimer patients? Does TREM2 also have a protective effect in the human brain? In earlier work, teams led by Haass and Ewers had also shown that the concentration of TREM2 is elevated in samples of CSF obtained from Alzheimer patients, most probably as a result of the activation of microglia in response to the pathological changes associated with the condition. However, the crucial issue remained unresolved: Do higher levels of TREM2 represent a protective or a deleterious response to these changes?

In order to answer this question, Ewers, Haass and their colleagues set out to establish a statistical correlation between the concentration of TREM2 in the CSF samples from their patient population and the rate of disease progression in these individuals over several years. They made use of data for 385 patients, collected by the “Alzheimer’s Disease Neuroimaging Initiative” (ADNI), a large clinical dataset comprising medical records and samples obtained not only from Alzheimer patients, but also from healthy seniors taken at regular checkups for many years. These data should make it possible to discern any meaningful associations between specific biochemical changes and the clinical course of Alzheimer’s.

Indeed Ewers und Haass were able to confirm that higher concentrations of TREM2 are linked to a more favorable prognosis at all stages of the disease. In these subjects, memory was less unstable and the rate of shrinkage of the hippocampus – a region of the brain that plays a vital role in learning and memory ¬– was less pronounced. “Our findings are of clinical relevance, because these patients displayed a consistently reduced risk of developing dementia over a period of 11 years,” says Ewers. “However, activation of the microglia is a double-edged sword. In addition to providing protective effects, it can lead to inflammation processes. Nevertheless, TREM2 could play a key role in triggering a protective immune response in the brains of patients with Alzheimer’s disease.”

The concentration of TREM2 in the CSF usually increases during the early stages of the disease, when the first symptoms appear. “TREM2 production is a response to brain damage that has already occurred,” Haass explains. “The protein stimulates the microglia to protect the brain. However, this protection does not seem to be sufficient in patients with Alzheimer’s disease.” This is where Haass and his colleagues see an option for new therapeutic strategies. “We are currently developing a therapeutic antibody that stimulates the TREM2 function and thus improves its protective effect,” he says.

Original publication:
"Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer’s disease"; Michael Ewers, Nicolai Franzmeier, Marc Suárez-Calvet et al.; Science Translational Medicine; 2019

Facts, background information, dossiers

  • Alzheimer’s disease
  • brain

More about LMU

  • News

    DNA repair: Opening the hatch to heal the break

    LMU researchers have determined the structure of a key enzyme complex that is involved in DNA repair, and traced the cycle of conformational changes that it undergoes while performing its biochemical function. Various types of DNA damage can have serious repercussions, both for the individu ... more

    One transistor for all purposes

    In mobiles, fridges, planes – transistors are everywhere. But they often operate only within a restricted current range. LMU physicists have now developed an organic transistor that functions perfectly under both low and high currents. Transistors are semiconductor devices that control volt ... more

    Tiny “blinkers” reveal molecules inside cells

    LMU physicists led by Ralf Jungmann introduce an entirely new approach to super-resolution microscopy: Tiny ‘blinkers’ enable simultaneous imaging of multiple biomolecules. In everyday life, blinking lights can send signals – for example, that a car is going to turn. Now, researchers have e ... more

  • Authors

    Prof. Dr. Thomas Carell

    Thomas Carell graduated in chemistry, completing his doctorate at the Max Planck Institute for Medical Research under the tutelage of Prof. Dr Dr H. A. Staab. Following a research position in the USA, he accepted a position at ETH Zurich, setting up his own research group in the Laboratory ... more

More about Deutsches Zentrum für Neurodegenerative Erkrankungen

  • News

    Researchers Identify Key Proteins for the Repair of Nerve Fibers

    Scientists at the German Center for Neurodegenerative Diseases (DZNE) have identified a group of proteins that help to regenerate damaged nerve cells. It is commonly accepted that neurons of the central nervous system shut down their ability to grow when they no longer need it; this occurs ... more

    Defective immune cells in the brain cause Alzheimer’s disease

    Mutations of the TREM2 gene can significantly increase the risk of Alzheimer's disease. Scientists from the German Center for Neurodegenerative Diseases (DZNE) and the Ludwig-Maximilians-University Munich now shed light on the reasons why TREM2 is so important for brain health. They show th ... more

q&more – the networking platform for quality excellence in lab and process

The q&more concept is to increase the visibility of recent research and innovative solutions, and support the exchange of knowledge. In the broad spectrum of subjects covered, the focus is on achieving maximum quality in highly innovative sectors. As a modern knowledge platform, q&more offers market participants one-of-a-kind networking opportunities. Cutting-edge research is presented by authors of international repute. Attractively presented in a high-quality context, and published in German and English, the original articles introduce new concepts and highlight unconventional solution strategies.

> more about q&more

q&more is supported by:

 

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE